¼¼°èÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå
Flowable Hemostats
»óǰÄÚµå : 1780819
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 376 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,209,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,629,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

À¯µ¿¼º ÁöÇ÷Á¦ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 9¾ï 2,390¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 7¾ï 4,220¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â À¯µ¿¼º ÁöÇ÷Á¦ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 3.7%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 9¾ï 2,390¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®µÇ°í ÀÖ´Â ºÎ¹® Áß ÇϳªÀÎ ¼Ò´Â CAGR 3.1%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 1,650¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. µÅÁö ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 2¾ï 220¸¸ ´Þ·¯, Áß±¹Àº CAGR 6.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀº 2024³â¿¡ 2¾ï 220¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2024³âºÎÅÍ 2030³â±îÁö CAGR 6.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1¾ï 8,460¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.5%¿Í 2.8%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.1%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¿Ü°ú ¼ö¼ú¿¡¼­ À¯µ¿¼º ÁöÇ÷Á¦ ¼ö¿ä°¡ Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

À¯µ¿¼º ÁöÇ÷Á¦´Â ¼ö¼ú Áß ÃâÇ÷À» Á¶ÀýÇÏ´Â µ¥ »ç¿ëµÇ¸ç, ÃÖ¼Òħ½À ¼ö¼ú ¹× ¿Ü»ó Ä¡·áÀÇ È¿°ú·Î ÀÎÇØ ³Î¸® äÅõǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á©¶óƾ ¶Ç´Â Äݶó°Õ ±â¹Ý ¾à¹°Àº º¹ÀâÇÑ ¼ö¼ú ºÎÀ§¿¡ ½Å¼ÓÇÑ ÁöÇ÷À» Á¦°øÇϱ⠶§¹®¿¡ ½ÉÇ÷°ü ¼ö¼ú, Á¤Çü¿Ü°ú, ½Å°æ ¿Ü°ú ¼ö¼ú¿¡ ÇʼöÀûÀÔ´Ï´Ù. ¿Ü°úÀû °³ÀÔÀÌ ÇÊ¿äÇÑ ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ¿Ü·¡ ¼ö¼ú ¼¾ÅÍÀÇ È®ÀåÀ¸·Î ÀÎÇØ °í±Þ ÁöÇ÷ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚÀÇ ¾ÈÀü°ú ¼ö¼úÀÇ È¿À²¼ºÀÌ ÃÖ¿ì¼± °úÁ¦·Î ¶°¿À¸£¸é¼­ À¯µ¿¼º ÁöÇ÷Á¦´Â ±âÁ¸ÀÇ °ÅÁ ºÀÇջ縦 ´ëüÇÒ ¼ö ÀÖ´Â ´ë¾ÈÀ¸·Î ¼±È£µÇ°í ÀÖ½À´Ï´Ù.

¾î¶² ±â¼ú ¹ßÀüÀÌ À¯µ¿¼º ÁöÇ÷Á¦¸¦ °³¼±Çϰí Àִ°¡?

»ýü°øÇÐ À¯µ¿¼º ÁöÇ÷Á¦, AI¸¦ Ȱ¿ëÇÑ ¼ö¼ú ¸ð´ÏÅ͸µ, »ýºÐÇØ¼º Á¦Á¦ÀÇ Çõ½ÅÀÌ À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. Æ®·Òºó ÇÔÀ¯ À¯µ¿¼º ÁöÇ÷Á¦ ¹× ÇǺ기 ±â¹Ý À¯µ¿¼º ÁöÇ÷Á¦ÀÇ °³¹ß·Î ÀÀ°í ¼Óµµ¿Í È¿°ú°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. AI¸¦ Ȱ¿ëÇÑ ¿¹Ãø ºÐ¼®Àº ¿Ü°ú ÀÇ»çÀÇ ÃâÇ÷ À§Çè Æò°¡¿Í À¯µ¿¼º ÁöÇ÷Á¦ Àû¿ë ÃÖÀûÈ­¸¦ µ½°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ýüÈí¼ö¼º À¯µ¿¼º ÁöÇ÷Á¦¿Í Ç×±Õ¼º À¯µ¿¼º ÁöÇ÷Á¦ÀÇ µîÀåÀ¸·Î °¨¿° À§ÇèÀ» ÁÙ¿© ¼ö¼ú ÈÄ °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ·Îº¿ º¸Á¶ ¼ö¼ú°ú ÀÚµ¿ À¯µ¿¼º ÁöÇ÷Á¦ °ø±Þ ½Ã½ºÅÛÀÇ ÅëÇÕÀº ¿Ü°úÀû °³ÀÔÀÇ Á¤È®¼ºÀ» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀÇ ¹ßÀüÀ¸·Î À¯µ¿¼º ÁöÇ÷Á¦´Â ´õ¿í È¿°úÀûÀÌ°í ¾ÈÀüÇÏ¸ç ´Ù¾çÇÑ ¼ö¼ú ȯ°æ¿¡ ÀûÀÀÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

±ÔÁ¦¿Í ½ÃÀå µ¿ÇâÀº À¯µ¿¼º ÁöÇ÷Á¦¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡°í Àִ°¡?

FDA, EMA, WHOÀÇ ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â À¯µ¿¼º ÁöÇ÷Á¦ÀÇ °³¹ß ¹× »óǰȭ¸¦ Çü¼ºÇÏ°í »ýüÀûÇÕ¼º ¹× ¾ÈÀü¼º ±âÁØÀ» ÁؼöÇϵµ·Ï º¸ÀåÇÕ´Ï´Ù. ºñ¿ë È¿À²ÀûÀÎ ¼ö¼ú Ä¡·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¿Ü·¡ ȯÀÚ ¹× ¿Ü·¡ ȯÀÚ È¯°æ¿¡¼­ ÷´Ü À¯µ¿¼º ÁöÇ÷Á¦ÀÇ Ã¤ÅÃÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÃÖ¼Òħ½À ¼ö¼ú·ÎÀÇ ÀüȯÀº º¹°­°æ ¼ö¼ú ¹× ·Îº¿ º¸Á¶ ¼ö¼ú¿¡¼­ À¯µ¿¼º ÁöÇ÷Á¦ÀÇ Àû¿ëÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. ÀÏȸ¿ë ÁöÇ÷ ÁÖ»ç±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼ö¼ú ¿öÅ©Ç÷ο츦 ´õ¿í °£¼ÒÈ­ÇÏ°í ¿À¿° À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ±ÔÁ¦ ¿ä°Ç°ú ¼ö¼ú ¼±È£µµ°¡ ÁøÈ­ÇÔ¿¡ µû¶ó À¯µ¿¼º ÁöÇ÷Á¦´Â Çö´ë ÀÇ·á¿¡ ¾ø¾î¼­´Â ¾È µÉ ÇʼöǰÀÌ µÇ°í ÀÖ½À´Ï´Ù.

À¯µ¿¼º ÁöÇ÷Á¦ ½ÃÀåÀÇ ÇâÈÄ ¼ºÀå µ¿·ÂÀº?

À¯µ¿¼º ÁöÇ÷Á¦ÀÇ ¹Ì·¡´Â ¹ÙÀÌ¿À ¿£Áö´Ï¾î¸µ ÀÀ°íÁ¦, AI Áö¿ø ¼ö¼ú ±â¼ú, ¸ÂÃãÇü ÀÇ·áÀÇ È®´ë Àû¿ë µîÀÇ ¹ßÀüÀ¸·Î Çü¼ºµÇ°í ÀÖ½À´Ï´Ù. Ç¥Àû ÀÀ°í ¸ÞÄ¿´ÏÁòÀ» °¡Áø ³ª³ë±â¼ú ±â¹ÝÀÇ À¯µ¿¼º ÁöÇ÷Á¦ °³¹ßÀº ÃâÇ÷ Á¶ÀýÀÇ Á¤È®µµ¸¦ ³ôÀÏ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ½Ç½Ã°£ AI¸¦ Ȱ¿ëÇÑ ¼ö¼ú ºÐ¼®ÀÇ ÅëÇÕÀº À¯µ¿¼º ÁöÇ÷Á¦ Àû¿ëÀ» ´õ¿í ÃÖÀûÈ­Çϰí ȯÀÚ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àç»ýÀÇ·á¿Í Á¶Á÷°øÇÐÀÇ È®´ë·Î »ýüÈí¼ö¼º ÁöÇ÷Àç¿Í Áٱ⼼Æ÷ ±â¹Ý ÁöÇ÷ÀçÀÇ ±â¼ú Çõ½ÅÀÌ ÁøÇàµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼ö¼ú ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² À¯µ¿¼º ÁöÇ÷Á¦´Â ¼ö¼úÀÇ È¿À²¼º°ú ȯÀÚÀÇ ¾ÈÀü¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ºÎ¹®

À¯·¡(¼Ò, µÅÁö), ¿ëµµ(ÀϹݿܰú, ½ÉÇ÷°ü¿Ü°ú, Á¤Çü¿Ü°ú, ºÎÀΰú ¿Ü°ú, ½Å°æ¿Ü°ú, Àç°Ç¿Ü°ú, ±âŸ ¿ëµµ), ÃÖÁ¾ ¿ëµµ(º´¿ø¡¤Å¬¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ ÃÖÁ¾ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°è °íÀ¯ÀÇ SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡°¡ ¼±º°ÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Flowable Hemostats Market to Reach US$923.9 Million by 2030

The global market for Flowable Hemostats estimated at US$742.2 Million in the year 2024, is expected to reach US$923.9 Million by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Bovine, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$616.5 Million by the end of the analysis period. Growth in the Porcine segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$202.2 Million While China is Forecast to Grow at 6.8% CAGR

The Flowable Hemostats market in the U.S. is estimated at US$202.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$184.6 Million by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Flowable Hemostats Market - Key Trends & Drivers Summarized

Why Is the Demand for Flowable Hemostats Increasing in Surgical Procedures?

Flowable hemostats, used to control bleeding during surgical procedures, are gaining widespread adoption due to their efficacy in minimally invasive surgeries and trauma care. These gelatin- or collagen-based agents provide rapid hemostasis in complex surgical sites, making them essential in cardiovascular, orthopedic, and neurosurgical applications. The rising prevalence of chronic diseases requiring surgical intervention, coupled with the expansion of ambulatory surgical centers, is fueling demand for advanced hemostatic solutions. Additionally, as patient safety and surgical efficiency become top priorities, flowable hemostats are emerging as a preferred alternative to traditional gauze and sutures.

What Technological Advancements Are Improving Flowable Hemostats?

Innovations in bioengineered hemostatic agents, AI-powered surgical monitoring, and biodegradable formulations are transforming the flowable hemostat market. The development of thrombin-infused and fibrin-based hemostats is enhancing clotting speed and efficacy. AI-driven predictive analytics are assisting surgeons in assessing bleeding risks and optimizing hemostat application. Additionally, the rise of bioabsorbable and antimicrobial hemostatic agents is improving post-surgical outcomes by reducing infection risks. The integration of robotic-assisted surgery with automated hemostat delivery systems is further enhancing precision in surgical interventions. These technological advancements are making flowable hemostats more effective, safer, and adaptable to various surgical settings.

How Are Regulations and Market Trends Influencing Flowable Hemostats?

Stringent regulatory frameworks by the FDA, EMA, and WHO are shaping the development and commercialization of flowable hemostats, ensuring compliance with biocompatibility and safety standards. The increasing focus on cost-effective surgical care is driving the adoption of advanced hemostatic agents in outpatient and ambulatory settings. Additionally, the shift toward minimally invasive procedures is expanding the application of flowable hemostats in laparoscopic and robotic-assisted surgeries. The growing demand for single-use, pre-filled hemostatic syringes is further streamlining surgical workflows and reducing contamination risks. As regulatory requirements and surgical preferences evolve, flowable hemostats are becoming integral to modern healthcare practices.

What’s Driving the Future Growth of the Flowable Hemostats Market?

The future of flowable hemostats is being shaped by advancements in bioengineered clotting agents, AI-assisted surgical techniques, and the increasing adoption of personalized medicine. The development of nanotechnology-based hemostatic agents with targeted clotting mechanisms is expected to enhance precision in bleeding control. The integration of real-time AI-powered surgical analytics will further optimize hemostat application, improving patient outcomes. Additionally, the expansion of regenerative medicine and tissue engineering is expected to drive innovation in bioresorbable and stem cell-based hemostatic products. As surgical technology evolves, flowable hemostats will continue to play a vital role in improving surgical efficiency and patient safety.

SCOPE OF STUDY:

The report analyzes the Flowable Hemostats market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Origin (Bovine, Porcine); Application (General surgery, Cardiovascular surgery, Orthopedic surgery, Gynecological surgery, Neurosurgery, Reconstructive surgery, Other applications); End-Use (Hospitals & Clinics, Ambulatory Surgery Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â